The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival

Carcinogenesis

Volumn 35, Issue 7, 2014, Pages 1491-1499

  Hu, Yunping ^a   Mintz, Akiva ^a   Shah, Sagar R ^b   Quinones Hinojosa, Alfredo ^b   Hsu, Wesley ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; CHORDOMA; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHORDOMA; EPITHELIAL-MESENCHYMAL TRANSITION; FETAL PROTEINS; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS;

EID: 84903945206     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu014     Document Type: Article

References (46)

1. McMaster,M.L. et al. (2001) Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control, 12, 1-11.
2. Bergh,P. et al. (2000) Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer, 88, 2122-2134.
3. Volpe,R. et al. (1983) A clinicopathologic review of 25 cases of chordoma (a pleomorphic and metastasizing neoplasm). Am. J. Surg. Pathol., 7, 161-170.
4. Gay,E. et al. (1995) Chordomas and chondrosarcomas of the cranial base:results and follow-up of 60 patients. Neurosurgery, 36, 887-96; discussion 896.
5. Park,L. et al. (2006) Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int. J. Radiat. Oncol. Biol. Phys., 65, 1514-1521.
6. Yang,X.R. et al. (2009) T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat. Genet., 41, 1176-1178.
7. Capellini,T.D. et al. (2008) Conservation of notochord gene expression across chordates: insights from the Leprecan gene family. Genesis, 46, 683-696.
8. Showell,C. et al. (2004) T-box genes in early embryogenesis. Dev. Dyn., 229, 201-218.
9. Imajyo,I. et al. (2012) T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma. Int. J. Oncol., 41, 1985-1995.
10. Shimoda,M. et al. (2012) The T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stemlike cells in adenoid cystic carcinoma cells. BMC Cancer, 12, 377.
11. Roselli,M. et al. (2012) Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin. Cancer Res., 18, 3868-3879.
12. Barresi,V. et al. (2012) Expression of brachyury in hemangioblastoma:potential use in differential diagnosis. Am. J. Surg. Pathol., 36, 1052-1057.
13. Kilic,N. et al. (2011) Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur. J. Cancer, 47, 1080-1085.
14. Vujovic,S. et al. (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J. Pathol., 209, 157-165.
15. Sarkar,D. et al. (2012) BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells. Int. J. Cancer, 130, 328-337.
16. Presneau,N. et al. (2011) Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J. Pathol., 223, 327-335.
17. Hsu,W. et al. (2011) Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. J. Neurosurg., 115, 760-769.
18. Fernando,R.I. et al. (2010) The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J. Clin. Invest., 120, 533-544.
19. Nelson,A.C. et al. (2012) An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. J. Pathol., 228, 274-285.
20. Nakatani,Y. et al. (1996) Basic fibroblast growth factor induces notochord formation and the expression of As-T, a Brachyury homolog, during ascidian embryogenesis. Development, 122, 2023-2031.
21. Ciruna,B.G. et al. (1997) Chimeric analysis of fibroblast growth factor receptor-1 (Fgfr1) function: a role for FGFR1 in morphogenetic movement through the primitive streak. Development, 124, 2829-2841.
22. Pearson,G. et al. (2001) Mitogen-activated protein (MAP) kinase pathways:regulation and physiological functions. Endocr. Rev., 22, 153-183.
23. Umbhauer,M. et al. (1995) Mesoderm induction in Xenopus caused by activation of MAP kinase. Nature, 376, 58-62.
24. Hoffmann,A. et al. (2002) The T-box transcription factor Brachyury mediates cartilage development in mesenchymal stem cell line C3H10T1/2. J. Cell Sci., 115, 769-781.
25. Wang,S. et al. (2004) QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc. Natl Acad. Sci. USA, 101, 4833-4838.
26. Casey,E.S. et al. (1998) The T-box transcription factor Brachyury regulates expression of eFGF through binding to a non-palindromic response element. Development, 125, 3887-3894.
27. Sun,X. et al. (1999) Targeted disruption of Fgf8 causes failure of cell migration in the gastrulating mouse embryo. Genes Dev., 13, 1834-1846.
28. Ornitz,D.M. et al. (2001) Fibroblast growth factors. Genome Biol., 2, Reviews 3005.
29. Javerzat,S. et al. (2002) The role of fibroblast growth factors in vascular development. Trends Mol. Med., 8, 483-489.
30. Kwabi-Addo,B. et al. (2004) The role of fibroblast growth factors and their receptors in prostate cancer. Endocr. Relat. Cancer, 11, 709-724.
31. Marsh,S.K. et al. (1999) Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene, 18, 1053-1060.
32. Tarkkonen,K.M. et al. (2012) Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One, 7, e49970.
33. Shingu,K. et al. (1998) Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions. Endocr. J., 45, 35-43.
34. Ozen,M. et al. (2004) Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor. Melanoma Res., 14, 13-21.
35. Marek,L. et al. (2009) Fibroblast growth factor (FGF) and FGF receptormediated autocrine signaling in non-small-cell lung cancer cells. Mol. Pharmacol., 75, 196-207.
36. Cheng,A.L. et al. (2011) Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology, 81, 372-380.
37. Wesche,J. et al. (2011) Fibroblast growth factors and their receptors in cancer. Biochem. J., 437, 199-213.
38. Tomlinson,D.C. et al. (2009) Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res., 69, 4613-4620.
39. Marshall,M.E. et al. (2011) Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin. Cancer Res., 17, 5016-5025.
40. Deniz,M.L. et al. (2002) Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence. Neurosurgery, 51, 753-60; discussion 760.
41. Shalaby,A.A. et al. (2009) Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Mod. Pathol., 22, 996-1005.
42. Presneau,N. et al. (2009) Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br. J. Cancer, 100, 1406-1414.
43. Yao,Y. et al. (2003) Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. Proc. Natl Acad. Sci. USA, 100, 12759-12764.
44. Schulte-Merker,S. et al. (1995) Mesoderm formation in response to Brachyury requires FGF signalling. Curr. Biol., 5, 62-67.
45. Latinkić,B.V. et al. (1997) The Xenopus Brachyury promoter is activated by FGF and low concentrations of activin and suppressed by high concentrations of activin and by paired-type homeodomain proteins. Genes Dev., 11, 3265-3276.
46. Olivera-Martinez,I. et al. (2012) Loss of FGF-dependent mesoderm identity and rise of endogenous retinoid signalling determine cessation of body axis elongation. PLoS Biol., 10, e1001415.